
Adam Mendelsohn, PhD
Co-Founder and CEO,
Vivani Medical, Inc.
United States
Dr. Mendelsohn has served as Vivani's Chief Executive Officer and as a member of its Board of Directors since the merger of Nano Precision Medical Inc. and Second Sight Medical Products Inc. in 2022. Prior to this, Dr. Mendelsohn served as the Chief Executive Officer of Nano Precision Medical from 2009 until 2022. Dr. Mendelsohn received his Ph.D. in bioengineering at the UC San Francisco/UC Berkeley Joint Graduate Group in Bioengineering, Class of 2011, during which he was awarded an NSF fellowship to perform research at Kyoto University and published multiple peer-reviewed articles describing new treatment options for Type 1 diabetes through the immuno-isolated transplantation of insulin-producing cells under the direction of Professor Tejal A. Desai. While in graduate school, Dr. Mendelsohn served as the director for the Venture Innovation Program in Life Sciences and completed his certificate in Management of Technology with the Haas School of Business. Dr. Mendelsohn has served as a Technical Advisor to the Alfred E. Mann Institute for Biomedical Engineering at USC, a fellow of the Startup Leadership Program, the President of UCSF’s Graduate Division Alumni Association and is currently a board member of the Maestro Foundation.